Gastrointestinal disturbances with obesity.
Steatosis and steatohepatitis are associated with obesity. Despite florid histological changes, patients with non-alcoholic steatohepatitis generally remain asymptomatic, and it usually runs a relatively benign course. An elevated insulin level may be important in the pathogenesis. There is a marked regression of fatty changes after weight reduction. In obese subjects the risk of developing gallstones is increased due to an increased saturation of gallbladder bile with cholesterol and possible gallbladder stasis. During weight reduction with very low calorie diets the incidence in gallstones increases probably because of an increased saturation of bile during the loss of weight. Ursodeoxycholic acid appears to be a promising prophylactic agent. Chenodeoxycholic acid is not useful for these subjects. There is controversy over whether obesity contributes to gastroesophageal reflux and gastric emptying disturbances. There are changes in gastrointestinal peptide plasma levels in obesity but it is not clear if this contributes to its development. The risk for high-risk colorectal adenomas and carcinomas is reported to be increased in obese males. Vertical banded gastroplasty and gastric bypass procedures are nowadays the surgical options for the treatment of obesity. Nutritional deficiencies, particularly of vitamin B12, folate and iron are common after gastric bypass and must be sought and treated. Dumping is another potential complication of this operation. If stenosis and gastric outlet obstruction develop endoscopic dilatation is a good therapeutic option.
Dept. of Gastroenterology and Hepatology, University Hospital Leiden, The Netherlands.
R J
RJ
Lieverse
J B
JB
Jansen
A A
AA
Masclee
C B
CB
Lamers
D000818:Animals; D001839:Bombesin / Q000097:blood; D002766:Cholecystokinin / Q000097:blood; D002769:Cholelithiasis / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D004035:Diet Therapy / Q000009:adverse effects; D005234:Fatty Liver / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D005235:Fatty Liver, Alcoholic / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D005767:Gastrointestinal Diseases / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D005769:Gastrointestinal Motility; D005770:Gastrointestinal Neoplasms / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D006801:Humans; D008297:Male; D009765:Obesity / Q000150:complications*; D010455:Peptides / Q000097:blood; D010523:Peripheral Nervous System Diseases / Q000150:complications; D012307:Risk Factors
D010455:Peptides; D002766:Cholecystokinin; D001839:Bombesin